Ceritinib

證據等級: L5

預測適應症: 10 個

Ceritinib: From ALK-Positive Non-Small Cell Lung Cancer to Fibromatosis, Gingival

One-Sentence Summary

Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor, globally approved for the treatment of ALK-rearranged non-small cell lung cancer (NSCLC), and is not currently registered in Taiwan. The TxGNN model predicts it may be effective for Fibromatosis, Gingival, however this prediction is backed by 0 clinical trials and 0 publications — it rests entirely on knowledge graph topology with no direct biological rationale.

Quick Overview

Item	Content
Original Indication	ALK-positive non-small cell lung cancer (global approval; no Taiwan license on record)
Predicted New Indication	Fibromatosis, Gingival
TxGNN Prediction Score	99.86%
Evidence Level	L5
Taiwan Market Status	✗ Not Marketed (未上市)
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available from the data source. Based on published literature, ceritinib is a potent, orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK). It was the first drug to overcome crizotinib resistance in ALK-positive NSCLC, demonstrating robust efficacy in the landmark ASCEND-4 Phase 3 trial, which established its superiority over platinum-based chemotherapy in untreated patients. Beyond ALK, ceritinib also inhibits IGF-1R (insulin-like growth factor 1 receptor) and FAK (focal adhesion kinase), pathways relevant to cell survival and invasion in solid tumours.

Gingival fibromatosis is a benign, non-malignant overgrowth of fibrous gingival tissue. Its primary molecular drivers are mutations in SOS1 and FGFR (fibroblast growth factor receptor), and it is fundamentally a structural, connective tissue disorder — not a malignancy driven by oncogenic kinase fusion. There is currently no known role for ALK, ROS1, IGF-1R, or FAK signalling in the pathogenesis of this condition. The mechanistic bridge between ceritinib’s pharmacology and gingival fibromatosis biology does not exist in current evidence.

The high TxGNN prediction score (99.86%) most likely reflects graph-level proximity in the underlying knowledge graph, where “fibrous tissue proliferation” disease nodes are statistically close to nodes associated with ceritinib. This is a known artefact of graph-based models: hub nodes with high connectivity generate confident predictions that do not always reflect biological plausibility. This prediction should be treated as a computational signal only, requiring experimental validation before any further investment.

Clinical Trial Evidence

Currently no related clinical trials registered for Ceritinib in Fibromatosis, Gingival.

Literature Evidence

Currently no related literature available for Ceritinib in Fibromatosis, Gingival.

Taiwan Market Authorization

No regulatory licenses for Ceritinib have been identified in the Taiwan TFDA database. Ceritinib is not approved or marketed in Taiwan.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No licenses on record

Note: Ceritinib (Zykadia®) holds FDA approval (US, 2014) and EMA approval (EU, 2015) for ALK-positive NSCLC, but these authorizations fall outside the scope of this Taiwan regulatory dataset.

Cytotoxicity

Ceritinib is an antineoplastic agent — a targeted therapy for ALK-driven malignancy. It meets the antineoplastic criteria: its known global indication is a malignant condition (NSCLC), and it belongs to the tyrosine kinase inhibitor class used in oncology.

Item	Content
Cytotoxicity Classification	Targeted therapy — 2nd-generation ALK tyrosine kinase inhibitor
Myelosuppression Risk	Low (myelosuppression is not a primary toxicity of ALK-TKIs; neutropenia reported infrequently)
Emetogenicity Classification	Moderate (nausea, vomiting, and diarrhoea are the most common dose-limiting GI effects; substantially reduced when taken at 450 mg with food per ASCEND-8 data)
Monitoring Items	Liver function (ALT/AST/bilirubin), QTc interval (ECG), fasting blood glucose, lipase/amylase, CBC
Handling Protection	Handle as oral antineoplastic agent; follow institutional cytotoxic drug handling protocols

Safety Considerations

Please refer to the package insert for safety information. (No Taiwan-specific warnings, contraindications, or drug interaction data are available in the current dataset.)

Conclusion and Next Steps

Decision: Hold

Rationale: Ceritinib’s mechanism of action — centred on ALK/IGF-1R/FAK inhibition — has no established connection to gingival fibromatosis, a benign connective tissue disorder driven by SOS1/FGFR pathways. With zero supporting clinical trials or relevant literature and a purely graph-derived prediction signal, this indication does not meet the threshold for further repurposing investigation.

To proceed, the following is needed:

Evidence of ALK pathway activation in gingival fibromatosis tissue (e.g., immunohistochemistry or targeted sequencing data)
Complete MOA data from DrugBank to check whether ceritinib’s off-target kinase profile overlaps with FGFR or SOS1 signalling
Assessment of whether ceritinib’s IGF-1R inhibition has any theoretical relevance to mesenchymal fibrous proliferation
Taiwan TFDA package insert retrieval for complete local safety, contraindication, and drug interaction data (currently blocking initial safety assessment — Data Gap DG001)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.